Bis(maltolato)oxovanadium(IV)

SKU: orb1306036

Description

Bis(maltolato)oxovanadium(IV) (BMOV) is an orally active, competitive pan-protein tyrosine phosphatase (PTP) inhibitor with insulin-mimetic and anti-diabetic properties. It acts as an insulin sensitizer, improving cardiac function in diabetic models, and potently inhibits PTPs such as PTP1B (IC50 109 nM) and SHP2.

Research Area

Metabolism Research

Key Properties

• CAS Number: 38213-69-3
• MW: 317.15
• Purity: 99.10% (May vary between batches)
• Formula: C₁₂H₁₀O₇V
• SMILES: O=[V+2]12([O-]C=3C(=O1)C=COC3C)[O-]C=4C(=O2)C=COC4C
• Target: Phosphatase
• Solubility: DMSO:13 mg/mL (40.99 mM)

Bioactivity

• Target IC50:
  HCPTPA:126 nM (IC50)|HPTPβ:26 nM (IC50)|PTP1B:109 nM (IC50)|SHP2:201 nM (IC50)
• In Vivo:
  BMOV (0.75-3.0 mmol; intraperitoneal injection; twice weekly; for 6 weeks; Male C57BL/6J mice) treatment ameliorates the metabolic phenotype, as evidenced by reduced body weight, improved insulin sensitivity and glucose tolerance.
  Read more...
• In Vitro:
  BMOV treatment enhances the phosphorylation of the insulin receptor and of the insulin signalling key intermediate Akt. BMOV treatment also resultes in an increased glucose uptake in C2C12 cells.
  Read more...
• Animal Research:
  BMOV (0.75-3.0 mmol; intraperitoneal injection; twice weekly; for 6 weeks; Male C57BL/6J mice) treatment ameliorates the metabolic phenotype, as evidenced by reduced body weight, improved insulin sensitivity and glucose tolerance.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

diabetes, Bis(maltolato)oxovanadium, Bis(maltolato)oxovanadium (IV), Bis(maltolato)oxovanadium(IV), Bis maltolato oxovanadium,Bis(maltolato)oxovanadium (IV),bis maltolato oxo vanadium, BMOV, metabolic, inhibit, Inhibitor, insulin, HCPTPA, HPTPß, HPTPβ, glucose, PTP1B, PTP, phenotype, SHP-2, SHP-1, SHP2, Phosphatase, uptake, type-2

Compound Identifiers

PubChem CID

131853223